Alps Advisors Inc Exelixis, Inc. Transaction History

Alps Advisors Inc

$14.8 Billion
Q3 2024

A detailed history of Alps Advisors Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 13,000 shares of EXEL stock, worth $452,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,000

Holding current value

$452,790

% of portfolio

0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$21.96 - $27.6 $285,480 - $358,800	13,000 New	13,000 $337,000
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $188,522 - $250,956	-11,070 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$15.84 - $21.88 $38,174 - $52,730	-2,410 Reduced 17.88%	11,070 $202,000
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $47,840 - $62,045	-2,935 Reduced 17.88%	13,480 $285,000
Q2 2021 Aug 11, 2021	SELL	$17.95 - $25.56 $10,554 - $15,029	-588 Reduced 3.46%	16,415 $299,000
Q1 2021 May 07, 2021	SELL	$20.53 - $25.22 $296,514 - $364,252	-14,443 Reduced 45.93%	17,003 $384,000
Q4 2020 Feb 03, 2021	SELL	$18.39 - $24.8 $54,048 - $72,887	-2,939 Reduced 8.55%	31,446 $631,000
Q3 2020 Nov 04, 2020	BUY	$20.67 - $26.94 $173,834 - $226,565	8,410 Added 32.38%	34,385 $841,000
Q2 2020 Aug 05, 2020	BUY	$16.46 - $27.42 $427,548 - $712,234	25,975 New	25,975 $617,000
Q3 2019 Nov 04, 2019	SELL	$17.68 - $22.65 $286,858 - $367,496	-16,225 Closed	0 $0
Q2 2019 Aug 07, 2019	SELL	$18.93 - $24.75 $16,204 - $21,186	-856 Reduced 5.01%	16,225 $347,000
Q1 2019 May 01, 2019	SELL	$19.6 - $24.76 $283,808 - $358,524	-14,480 Reduced 45.88%	17,081 $407,000
Q4 2018 Feb 04, 2019	BUY	$13.65 - $21.8 $36,732 - $58,663	2,691 Added 9.32%	31,561 $621,000
Q3 2018 Oct 25, 2018	BUY	$15.87 - $22.4 $164,333 - $231,951	10,355 Added 55.93%	28,870 $512,000
Q2 2018 Aug 02, 2018	SELL	$18.56 - $22.45 $44,321 - $53,610	-2,388 Reduced 11.42%	18,515 $398,000
Q2 2018 Jul 25, 2018	SELL	$18.56 - $22.45 $237,289 - $287,023	-12,785 Reduced 37.95%	20,903 $635,000
Q1 2018 May 01, 2018	BUY	$22.15 - $31.89 $283,187 - $407,713	12,785 Added 61.16%	33,688 $746,000
Q4 2017 Feb 05, 2018	SELL	$24.23 - $30.93 $5.73 Million - $7.32 Million	-236,601 Reduced 91.88%	20,903 $635,000
Q3 2017 Nov 03, 2017	BUY	$23.35 - $29.24 $6.01 Million - $7.53 Million	257,504	257,504 $6.24 Million

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.17 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$1.02 Billion
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$885 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$535 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$399 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account